BVT Aktienanleihe MRK 28.06.2024/ DE000VM0BT10 /
15/05/2024 17:00:47 | Chg.+0.840 | Bid19:16:20 | Ask19:16:20 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
100.120EUR | +0.85% | 100.070 Bid Size: 50,000 |
100.570 Ask Size: 50,000 |
MERCK KGAA O.N. | 162.55 EUR | 28/06/2024 | Call |
GlobeNewswire
14:30
Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Cl...
GlobeNewswire
14:05
Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
14:00
PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results
GlobeNewswire
07/05
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire
06/05
Press Release Biocartis NV: Biocartis and Merck to Collaborate on Improving Patient Access to Person...
GlobeNewswire
04/03
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Ger...
GlobeNewswire
21/12/2023
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire
14/12/2023
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development an...
GlobeNewswire
17/10/2023
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA